

0001477932-24-005243S-1 SOBR Safe, Inc. 2024082320240823192633192633192633 0 0001477932-24-005243 S-1 22 20240826
20240823 SOBR Safe, Inc. 0001425627 2721 260731818 DE 1231 S-1 33 333-281773 241237557 6400 S. FIDDLERS GREEN
CIRCLE SUITE 1400 GREENWOOD VILLAGE CO 80111 844-762-7723 6400 S. FIDDLERS GREEN CIRCLE SUITE 1400
GREENWOOD VILLAGE CO 80111 TransBiotech, Inc. 20120302 IMAGINE MEDIA LTD 20080130 S-1 1 sobr_s1.htm FORM S-1
sobr_s1.htm0001425627S-1false00014256272024-01-012024-06-30iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesAs filed with
the Securities and Exchange Commission on August 23, 2024Registration No. 333-Â UNITED STATESSECURITIES AND
EXCHANGE COMMISSIONWashington, D.C. 20549Â Form S-1Â REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF
1933Â Â Â SOBR Safe, Inc.Â www.sobrsafe.com(Exact name of registrant as specified in its charter)Â DelawareÂ 3829Â 26-
0731818(State or other jurisdiction of incorporation or organization)Â (Primary Standard Industrial Classification Code
Number)Â (I.R.S. Employer Identification No.)Â 6400 S. Fiddlers Green Circle, Suite 1400Greenwood Village, Colorado
80111Â Â (844) 762-7723(Address, including zip code, of registrant)Â s principal executive offices)Â (Telephone number,
including area code)Â David Gandini, Chief Executive OfficerChristopher Whitaker, Chief Financial OfficerSOBR Safe, Inc.6400 S.
Fiddlers Green Circle, Suite 1400Greenwood Village, Colorado 80111(844) 762-7723(Name, address, including zip code, and
telephonenumber, including area code, of agent for service)Â Copies of all communications, including communications sent to
agent for service, should be sent to:Â Joseph M. Lucosky, Esq.Soyoung Lee, Esq.Lucosky Brookman LLP101 Wood Avenue South,
5th FloorIselin, New Jersey 08830Telephone: (732) 395-4400Fax: (732) 395-4401Â Â Approximate date of commencement of
proposed sale to the public:Â As soon as practicable after this Registration Statement becomes effective.Â If any of the securities
being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, check the following box. Â Â Â If this Form is filed to register additional securities for an offering pursuant to Rule 462(b)
under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. Â Â Â If this Form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective
registration statement for the same offering. Â Â Â If this Form is a post-effective amendment filed pursuant to Rule 462(d) under
the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective
registration statement for the same offering. Â Â Â Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of large accelerated filer,
accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):Â Large accelerated
filer Â Accelerated filer Â Non-accelerated filer Â Smaller reporting company Â (Do not check if a smaller reporting
company)Emerging growth company Â Â Â If an emerging growth company, indicate by check mark if the registrant has elected not
to use the extended transition period for complying with any new or revised accounting standards provided to Section 7(a)(2)(B) of
the Securities Act. Â Â Â The registrant hereby amends this registration statement on such date or dates as may be necessary to
delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement
shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the
registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may
determine.Â Â Â Â The information in this prospectus is not complete and may be changed.Â The Selling Stockholder named in
this prospectus may not sell these securities until the registration statement filed with the SEC is effective. This prospectus is not
an offer to sell and it is not soliciting an offer to buy these securities in any state where the offer or sale is not
permitted.Â Â PRELIMINARY PROSPECTUSSubject to Completion, Dated August 23, 2024Â Up to 20,638,326 shares of common
stockÂ SOBR SAFE, INC.Â This prospectus relates to the resale from time to time of an aggregate of up to 20,638,326 shares (the
Shares) of common stock, \$0.00001 par value (Common Stock) of SOBR Safe, Inc. (the Company) which
consists of 20,638,326 Shares underlying warrants to purchase Common Stock (each a Warrant and collectively, the
Warrants) sold pursuant to an Inducement Letter dated June 4, 2024, between the Company and the selling securityholders
(the Selling Securityholders) and a Common Stock Purchase Warrant dated June 4, 2024 (the Common Stock Purchase
Warrant). Each Warrant is convertible into one share of Common Stock upon exercise, exercisable immediately, for a term of 60
months, at an exercise price of \$0.27, subject to adjustment thereunder.Â If the Selling Securityholders exercise their Warrants in
full, the shares being registered for resale by the Selling Securityholders would represent approximately 35.4% of our current
issued and outstanding Common Stock.Â We will not receive any proceeds from the resale of these shares of common stock by the
Selling Securityholder.Â Our common stock is currently listed on the Nasdaq Capital Market under the symbol SOBR.
Â Investing in our common stock involves risks. SOBR Safe, Inc., currently has limited revenue, and limited assets, is in unound
financial condition, and you should not invest unless you can afford to lose your entire investment. See Risk Factors
beginning on page 11. Neither the Securities and Exchange Commission nor any state securities commission has approved or
disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a
criminal offense.Â The date of this prospectus is August 23, 2024Â Â Â Â TABLE OF CONTENTSÂ Â Â PageÂ Â Â Â Prospectus
SummaryÂ Â 5Â Summary of the OfferingÂ Â 9Â Risk FactorsÂ Â 10Â Special Note about Forward-Looking
StatementsÂ Â 11Â Use of ProceedsÂ Â 11Â Selling SecurityholdersÂ Â 12Â Plan of DistributionÂ Â 13Â Available
InformationÂ Â 14Â Incorporation of Certain Documents by ReferenceÂ Â 14Â Legal MattersÂ Â 15Â ExpertsÂ Â 15Â Â Â 3Table
of ContentsÂ Â ABOUT THIS PROSPECTUSÂ You should rely only on the information contained in or incorporated by reference
into this prospectus. Neither we nor the selling securityholder named herein (the Selling Securityholder) have authorized
anyone to provide you with information different from, or in addition to, that contained in or incorporated by reference into this
prospectus. This prospectus is an offer to sell only the securities offered hereby but only under circumstances and in jurisdictions
where it is lawful to do so. The information contained in or incorporated by reference into this prospectus is current only as of
their respective dates or on the date or dates that are specified in those documents. Our business, financial condition, results of
operations and prospects may have changed since those dates.Â MARKET AND INDUSTRY DATAÂ This prospectus includes
estimates regarding market and industry data that we prepared based on our managements knowledge and experience in the
markets in which we operate, together with information obtained from various sources, including publicly available information,
industry reports and publications, surveys, our customers, distributors, suppliers, trade and business organizations and other
contacts in the markets in which we operate. In some cases, we do not expressly refer to the sources from which this data is
derived. Management estimates are derived from publicly available information released by independent industry analysts and
third-party sources, as well as data from our internal research, and are based on assumptions made by us upon reviewing such
data and our knowledge of such industry and markets which we believe to be reasonable.Â In presenting this information, we have
made certain assumptions that we believe to be reasonable based on such data and other similar sources and on our knowledge
of, and our experience to date in, the markets for the products we distribute. Market share data is subject to change and may be
limited by the availability of raw data, the voluntary nature of the data gathering process and other limitations inherent in any
statistical survey of market shares. In addition, customer preferences are subject to change.Â CERTAIN TRADEMARKS, TRADE
NAMES AND SERVICE MARKSÂ This prospectus includes trademarks and service marks owned by us, including, without
limitation, SOBRsafe, , SOBRcheck, , SOBRsure, , and our logo, which are our property and are protected under applicable
intellectual property laws. This prospectus also contains trademarks, trade names and service marks of other companies, which
are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this
prospectus may appear without the Â®, ,  or SM symbols, but such references are not intended to indicate, in any way, that we
will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks,
trade names and service marks. We do not intend our use or display of other parties trademarks, trade names or service

marks to imply, and such use or display should not be construed to imply a relationship with, or endorsement or sponsorship of us by, these other parties.

Table of Contents

PROSPECTUS SUMMARY

You should read the following summary together with the more detailed information and the financial statements appearing elsewhere in this Prospectus. This Prospectus contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth under “Risk Factors” and elsewhere in this Prospectus. Unless the context indicates or suggests otherwise, references to “we,” “our,” “us,” “the Company,” or the “Registrant” refer to SOBR Safe, Inc., a Delaware corporation, and its subsidiary. SOBR SAFE, INC. Corporate Overview

On September 19, 2011, we, as Imagine Media, Ltd., a Delaware corporation, acquired approximately 52% of the outstanding shares of TransBiotech, Inc. (“TBT”), a California corporation, from TBT’s directors in exchange for 124,439 shares of our common stock. In January 2012, our Board of Directors amended our Certificate of Incorporation changing our name from Imagine Media, Ltd. to TransBiotech, Inc., and we acquired approximately 45% of the remaining outstanding shares of TBT in exchange for 109,979 shares of our common stock. With the acquisitions in September 2011 and January 2012 of TBT common stock, we own approximately 99% of the outstanding shares of TBT. As a result of the acquisitions, TBT’s business is our business, and, unless otherwise indicated, any references to “we” or “us” include the business and operations of TBT.

On March 9, 2020, our Board of Directors approved the amendment to our Certificate of Incorporation and stockholders holding 52% of our then outstanding voting stock approved an amendment to our Articles of Incorporation. The Certificate of Amendment to our Certificate of Incorporation was for the purpose of, among other things, changing our name from “TransBiotech, Inc.” to “SOBR Safe, Inc.” The Certificate of Amendment to our Certificate of Incorporation became effective with the State of Delaware on April 24, 2020.

Pursuant to approval of an application with Nasdaq to uplist our common stock to their exchange under the ticker symbol “SOBR,” our common stock began trading and quoted on the Nasdaq exchange on May 16, 2023. Prior to this uplist to the Nasdaq exchange, our common stock was quoted on the “OTCQB” tier of the OTC Markets under the ticker symbol “SOBR.” Our corporate offices are located at 6400 South Fiddlers Green Circle, Suite 1400, Greenwood Village, Colorado 80111, telephone number (844) 762-7723.

Business Operations, Outlook and Challenges

We provide non-invasive technologies to quickly and humanely identify the presence of alcohol in individuals. Our mission is to save lives, positively impact behavioral outcomes and individual wellness, increase workplace safety and productivity, and create significant economic benefits. Our non-invasive technologies are integrated within our scalable and patent-pending software platform, “SOBRsafe,” producing statistical, measurable business and user data. To that end, our “SOBRsafe,” software platform, along with our integrated hardware devices used to provide non-invasive alcohol detection and identity verification, combine to create a robust solution that has current and potential applications in:

- Behavioral health and wellness
- Judicial administrative applications
- Licensing and integration
- Commercial environments, including but not limited to oil and gas, fleet management, telematics, ride share programs, and general workplace safety
- Individual consumer use, including co-parenting trust, personal accountability, and teen driver safety

Table of Contents

SOBRcheck,

Our “SOBRcheck,” device is a patent-pending, touch-based identity verification and alcohol detection solution. Users place two fingers on the device sensors, one compares biometric data points from the finger to confirm identity, while the other senses alcohol released through the pores of the fingertip. The touch-based device connects to the “SOBRsafe,” software solution to collect, present and communicate data collected to subscribed parties. The “SOBRcheck,” device has been in commercial production since the first quarter of 2022 and we have executed customer agreements since that time.

SOBRsure,

Our “SOBRsure,” device is a patent-pending, fitness-style wearable band with an alcohol detection solution intended for discrete, low-profile and voluntary use providing real-time alcohol monitoring and GPS tracking. The wearable band is a device which includes a contained sensor which senses alcohol released through the pores of the skin. The wearable band connects to a mobile device via Bluetooth communication where the “SOBRsafe,” mobile application collects and transmits data to the “SOBRsafe,” software solution. The “SOBRsure,” device provides passive, real-time alcohol insights to administrators, clinicians, parents and more, and also includes device removal and service interruption notifications. The “SOBRsure,” is in commercial production and became available for sale in late September 2023.

Our “SOBRsafe,” technology can also be deployed across numerous additional devices for various uses. We are currently exploring possible integrations with existing telematics systems and licensing by non-competitive third parties. We believe our device portfolio approach could yield a substantial repository of user data – a potentially monetizable asset for statistical analytics. The opportunity to collect data points over time could enable the development of business and insurance liability benchmarking, through artificial intelligence (AI), powerful guidance for perpetual safety improvement and associated cost savings capture. By demonstrating substance-free environments, organizations could deliver a data-driven argument for lowering insurance premiums. We could potentially partner with insurance providers to mandate use of the “SOBRsafe,” devices and/or technology.

Table of Contents

Design, manufacturing, quality testing and distribution for all “SOBRsafe,” integrated devices takes place in the United States.

Our products continue to gain awareness and recognition through trade shows, media exposure, social media and product demonstrations. To generate sales, we have a three-part strategy: 1) direct sales to businesses and consumers, 2) enter into agreements with channel partners and 3) enter into licensing and integration agreements. We currently employ four highly experienced sales professionals facilitating direct sales and channel partner relationships. Licensing and integration opportunities with non-competitive third parties continue in preliminary stages. We anticipate hiring an expert in licensing and integrations in 2024 to formulate and execute an expansion plan.

Marketing

We have developed a marketing plan that includes:

- consumer and enterprise e-commerce web-solutions
- search engine optimization (SEO) and search engine marketing (SEM)
- digital and social media campaigns
- online paid advertising placements
- brand ambassadors, affiliate partners and social media influencers
- public relations initiatives and trade shows
- direct business to business target campaigns
- alcohol detection/testing channel partners
- territorial sales agents
- advocacy group alignment
- ongoing brand development and
- continuous pursuit of cutting-edge technologies for future integration.

As of August 23, 2024, we have retained four channel partners to augment our sales and marketing efforts, serving business customers with “SOBRsafe,” technology solutions, including the “SOBRcheck,” and “SOBRsure,” devices.

Intellectual Property

We possess the following patent and pending patent applications related to our “SOBRsafe,” system and related devices:

- 1) U.S. Patent No. 9,296,298, entitled “Alcohol detection system for vehicle driver testing with integral temperature compensation,” which expires in 2032.
- 2) U.S. Patent Application No. 17/996,996, entitled “Noninvasive Transdermal Alcohol Screening System,” and related foreign filings in Canada and Europe.
- 3) U.S. Patent Application No. 18/251,567, entitled “Wearable Data Collection Device With Non-Invasive Sensing,” and related foreign filings in Canada, Europe, and Mexico.
- 4) U.S. Provisional Patent Application No. 63,502,580, entitled “Vehicle Diagnostic Port Dongle for Preventing Vehicle Start.”

We are currently applying for the related patents to convert our Provisionals as part of our patent defense strategy. We applied for trademarks related to the “SOBRsafe,” system, “SOBRcheck,” and “SOBRsure,” and “SOBR” as standard characters with no specific formatting.

Government Regulation

As we utilize a unique “Pass/Fail” methodology that simply alerts to the presence of alcohol (as opposed to measuring a discrete BrAC) - information that may be used at the discretion of the employer (or counselor, parent, etc.) - we do not believe we will be subject to any government regulation in the targeted alcohol detection markets including Behavioral Health, Justice, Alcohol Rehabilitation, Consumer, Facility & Fleet, or Young Driver markets. In the Judicial market, regulations vary significantly by state; some states only allow for the use of certain methodologies like breath or urine, while others do not specify and there exists no regulated barrier to entry for a transdermal solution.

Table of Contents

Human Capital Resources and Employees

As of August 23, 2024, there are a total of 14 full time employees, including Company officers Chairman/Chief Executive Officer/Secretary, David Gandini, and Chief

Financial Officer, Christopher Whitaker. The employee base primarily operates from our corporate offices located in Greenwood Village, Colorado. Employees who operate remotely from our corporate offices primarily consist of territorial sales and business development representatives. The remainder of our workforce consists of professional consultants in supporting roles due to the size and nature of our business. Oversight and Management Our executive officers are tasked with leading our organization in managing employment-related matters, including recruiting and hiring, onboarding and training, compensation planning and talent management and development. We are committed to providing team members with the training and resources necessary to continually strengthen their skills. Our executive team is responsible for periodically reviewing development and training programs, diversity efforts, business ethics and compliance training, team member benefit programs and initiatives, including healthcare and other benefits, as well as our management development and succession planning practices. Management periodically reports to the Board and the Compensation Committee regarding our human capital measures and results that guide how we attract, compensate, retain and develop a workforce to enable our business strategies. Diversity, Equity and Inclusion We believe that a diverse workforce is critical to our success, and we continue to monitor and improve the application of our hiring, retention, compensation and advancement processes for women and underrepresented populations across our workforce, including persons of color, veterans and LGBTQ+ to enhance our inclusive and diverse culture. We continue to invest in recruiting diverse talent. Workplace Safety and Health A vital part of our business is providing our workforce with a safe, healthy and sustainable working environment. We focus on implementing change through workforce observation and feedback channels to recognize risk and continuously improve our processes.

Table of Contents SUMMARY OF THE OFFERING Securities offered by the Selling Securityholders Up to 20,638,326 shares of Common Stock issuable upon the exercise of 20,638,326 Warrants with an exercise price of \$0.27 per share. The exercise price is subject to adjustment in the event of the Company's entrance into an agreement to pursue stock dividends, stock splits, stock combinations, reclassifications, reorganizations, transactions or similar events affecting our Common Stock as described in the Common Stock Purchase Warrant. Each Warrant is exercisable for one share of Common Stock, subject to adjustment as described above. Each Warrant will be exercisable immediately upon issuance and will expire five years after the initial issuance date. The Selling Securityholder may not exercise any portion of the Warrant to the extent such exercise would cause the Selling Securityholder, together with its affiliates, attribution parties, and any other person or entity acting as a group, to beneficially own a number of shares of Common Stock which would exceed 4.99% of the then outstanding Common Stock following such exercise, as such percentage ownership is determined in accordance with the terms of the Warrant, except that upon notice from the Selling Securityholder to us, the Selling Securityholder may waive such limitation up to a percentage, not in excess of 9.99%.

This prospectus also relates to the offering of the shares of Common Stock issuable upon exercise of the Warrants. Common Stock offered by us None. Use of Proceeds We will not receive any proceeds from the sale of Shares of our Common Stock by the Selling Securityholders. However, we will receive proceeds from the exercise of the Warrants if exercised for cash. Common Stock prior to this offering 34,764,593 shares of our common stock as of August 12, 2024. Common Stock after this offering (1) 34,764,593 shares of our common stock as of August 23, 2024. Risk Factors Investing in our securities involves a high degree of risk. See the "Risk Factors" section of this prospectus and in the documents we incorporate by reference in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our securities.

(1) The shares of Common Stock outstanding after this offering is based on 34,764,593 shares outstanding as of August 12, 2024. The number excludes: 1,598,306 shares of our common stock issuable upon exercise of outstanding stock options at a weighted average exercise price of \$1.99 per share as of June 30, 2024.

Table of Contents RISK FACTORS Any investment in our securities involves a high degree of risk. You should consider carefully the following information, together with the other information contained in this Prospectus and in the "Risk Factors" section of the 2023 Form 10-K and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, each of which has been filed with the SEC and is incorporated by reference into this prospectus, before you decide to buy our common stock. We face risks in developing devices based on our SOBRsafe, platform, as well in marketing and selling such devices. If we are not successful in developing, marketing, and/or selling devices based on our SOBRsafe, platform we will not be successful in generating revenue. The following risks and risk factors incorporated by reference are material risks that we face. If any of the events or developments discussed below or in our documents incorporated by reference occur, our business, our ability to achieve revenues, our operating results and our financial condition could be seriously harmed. In such an event, the fair value of our common stock could decline, and you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our operations.

Risks Related to this Offering The Selling Securityholders may sell their shares of common stock in the open market, which may cause our stock price to decline. The Selling Securityholders may sell their shares of common stock being registered in this offering in the public market. That means that up to 20,638,326 shares of common stock, the number of shares being registered in this offering for sale by the Selling Securityholders if they exercise the Warrants, may be sold in the public market. Such sales will likely cause our stock price to decline. Sale of our common stock by the Selling Securityholders could encourage short sales by third parties, which could contribute to the further decline of our stock price. The significant downward pressure on the price of our common stock caused by the sale of material amounts of common stock could encourage short sales by third parties. Such an event could place further downward pressure on the price of our common stock.

Table of Contents SPECIAL NOTE ABOUT FORWARD-LOOKING STATEMENTS We have made forward-looking statements in this prospectus, including the sections entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Business," that are based on our management's beliefs and assumptions and on information currently available to our management. Forward-looking statements include the information concerning our possible or assumed future results of operations, business strategies, financing plans, competitive position, industry environment, potential growth opportunities, the effects of future regulation and the effects of competition. Forward-looking statements include all statements that are not historical facts and can be identified by the use of forward-looking terminology such as the words "believe," "expect," "anticipate," "intend," "plan," "estimate" or similar expressions. These statements are only predictions and involve known and unknown risks and uncertainties, including the risks outlined under "Risk Factors" and elsewhere in this prospectus. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee future results, events, levels of activity, performance or achievement. We are not under any duty to update any of the forward-looking statements after the date of this prospectus to conform these statements to actual results, unless required by law.

USE OF PROCEEDS This Prospectus relates to shares of our common stock owned by the Selling Securityholders and the shares of our common stock that may be acquired by the Selling Securityholders due to the exercise of their Warrants. We will not receive any proceeds from the sale of shares of common stock in this offering.

Table of Contents SELLING SECURITYHOLDERS The Common Stock being offered by the Selling Securityholders are those issuable to the Selling Securityholders upon exercise of the Warrants. We are registering the shares of Common Stock underlying the Warrants in order to permit the Selling Securityholders to offer the shares for resale from time to time. Except for the ownership of the Warrants, the Selling Securityholders have not had any material relationship with us within the past three years. The table below lists the Selling Securityholders (each individually, a "Selling Securityholder") and other information regarding the beneficial ownership of the shares of Common Stock by each of the Selling Securityholders. The second column lists the number of shares of Common Stock beneficially owned by each Selling Securityholders, based on its ownership of the Warrants, as of August 23, 2024, assuming exercise of the Warrants held by the Selling Securityholders on that date, without regard to any limitations on exercises. The third column lists the shares of Common Stock being offered by this prospectus by the Selling Securityholders. In accordance with the terms of a registration rights agreement with the Selling Securityholders, this

prospectus generally covers the resale of the sum of (i) the maximum number of shares of Common stock issuable upon exercise of the related Warrants, determined as if the outstanding Warrants were exercised in full, in each case, as of the trading day immediately preceding the date this registration statement was initially filed with the SEC, each as of the trading day immediately preceding the applicable date of determination and all subject to adjustment as provided in the registration right agreement, without regard to any limitations on the exercise of the Warrants. The fourth column assumes the sale of all of the shares offered by the Selling Securityholders pursuant to this prospectus. Under the terms of the Warrants, the Selling Securityholder may not exercise any portion of the Warrant to the extent such exercise would cause the Selling Securityholder, together with its affiliates, attribution parties, and any other person or entity acting as a group, to beneficially own a number of shares of Common Stock which would exceed 4.99% of the then outstanding Common Stock following such exercise, as such percentage ownership is determined in accordance with the terms of the Warrant, except that upon notice from the Selling Securityholder to us, the Selling Securityholder may waive such limitation up to a percentage, not in excess of 9.99%. The number of shares in the second and fourth columns do not reflect these limitations. The Selling Securityholders may sell all, some or none of their shares in this offering. See the section of this prospectus titled "Plan of Distribution." SELLING SECURITYHOLDER TABLE Name of Selling Securityholder Number of shares of Common Stock Owned Prior to Offering Maximum Number of shares of Common Stock to be Sold Pursuant to this Prospectus Number of shares of Common Stock Owned After Offering Armistice Capital, LLC(1) 20,638,326 (1) The securities are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be beneficially owned by: (i) Armistice Capital, LLC (the "Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. The warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the Selling Stockholder from exercising that portion of the warrants that would result in the Selling Stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The address of Armistice Capital Master Fund Ltd. is c/o Armistice Capital, LLC, 510 Madison Avenue, 7th Floor, New York, NY 10022. No Selling Securityholders have, or within the past three years has had, any position, office or material relationship with us or any of our predecessors or affiliates. 12 Table of Contents PLAN OF DISTRIBUTION Each Selling Securityholder of the securities and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on the principal trading market or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling Securityholder may use any one or more of the following methods when selling securities: A ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; A block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction; A purchases by a broker-dealer as principal and resale by the broker-dealer for its account; A an exchange distribution in accordance with the rules of the applicable exchange; A in the over-the-counter market; A in transactions otherwise than on these exchanges or systems or in the over-the-counter market; A privately negotiated transactions; A settlement of short sales; A in transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security; A through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; A a combination of any such methods of sale; or A any other method permitted pursuant to applicable law. The Selling Securityholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act of 1933, as amended (the "Securities Act"), if available, rather than under this prospectus. Broker-dealers engaged by the Selling Securityholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Securityholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule 2121. In connection with the sale of the securities or interests therein, the Selling Securityholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Securityholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Securityholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). 13 Table of Contents The Selling Securityholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be "underwriters" within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Securityholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities. The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify the Selling Securityholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. The Company agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Securityholders without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Securityholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by the Selling Securityholders or any other person. The Company will make copies of this prospectus available to the Selling Securityholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act). AVAILABLE INFORMATION We have filed with the SEC a Registration Statement on Form S-1 under the Securities Act of 1933, as amended, to register the shares held by the Selling Securityholders and the shares underlying the warrants held by the Selling Securityholders. This Prospectus, which constitutes a part of the Registration Statement on Form S-1, does not contain all of the information set forth in the Form S-1 or the exhibits filed therewith. For further information about us and our common stock, reference is made to our filings with the SEC since we are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended. Statements contained in this Offering Statement regarding the contents of any contract or any other document that is filed as an exhibit to this Offering Statements are not necessarily complete, and in each instance we refer you to the copy of such contract or other document filed as an exhibit to our filings. A copy of the our filings with the SEC may be inspected without charge at the public reference room maintained by the SEC, located at 100 F Street, NE,

Washington, DC 20549, and copies of all or any part of the registration statement may be obtained from that office upon the payment of the fees prescribed by the SEC. Please call the SEC at 1-800-SEC-0330 for further information about the public reference room. The SEC also maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of the website is www.sec.gov.**INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE** The SEC allows us to “incorporate by reference” information into this prospectus, which means that we can disclose important information to you by referring you to those documents and that the information in this prospectus is not complete and you should read the information incorporated by reference for more detail. We incorporate by reference in two ways. First, we list certain documents that we have already filed with the SEC. The information in these documents is considered part of this prospectus. Second, the information in documents that we file with the SEC in the future will update and supersede the current information in, and incorporated by reference in, this prospectus until we file a post-effective amendment that indicates the termination of the offering of the common stock made by this prospectus.

Table of Contents We incorporate by reference the documents listed below and any future filings we will make with the SEC under Section 13(a), 13(c), 14 or 15(d) of the Exchange Act (other than information furnished in Current Reports on Form 8-K filed under Item 2.02 or 7.01 of such form unless such form expressly provides to the contrary), including those made after the date of the initial filing of the registration statement of which this prospectus is a part and prior to effectiveness of such registration statement: Our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on April 1, 2024; Our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2024, and June 30, 2024, filed with the SEC on May 15, 2024, and August 12, 2024; Our Current Reports on Form 8-K filed with the SEC on January 5, 2024, March 5, 2024, April 12, 2024, May 20, 2024, June 4, 2024, June 6, 2024, July 26, 2024, and August 13, 2024; and Our preliminary and definitive proxy statements on PRE 14A and DEF 14A filed with the SEC on May 2, 2024, May 13, 2024, June 14, 2024, and June 24, 2024. The documents incorporated by reference into this prospectus are also available on our corporate website at www.sobrsafe.com/. We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, a copy of any or all of the information that has been incorporated by reference in this prospectus but not delivered with this prospectus. You may request a copy of this information at no cost, by writing or telephoning us at the following address or telephone number: SOBR Safe, Inc. 6400 S. Fiddlers Green Circle, Suite 1400 Greenwood Village, Colorado 80111 (844) 762-7723 Attention: Corporate Secretary. Except for the specific incorporated documents listed above, no information available on or through our website shall be deemed to be incorporated in this prospectus or the registration statement of which it forms a part. The SEC maintains an internet website that contains reports, proxy and information statements and other information regarding the issuers that file electronically with the SEC, including us, and can be accessed free of charge on the SEC’s website, <http://www.sec.gov>.

LEGAL MATTERS Lucosky Brookman LLP serves as our legal counsel in connection with this offering. **EXPERTS** The financial statements as of and for the fiscal year ended December 31, 2023 have been audited by Haynie & Company, an independent registered public accounting firm, as stated in their reports. The financial statements as of and for the fiscal years ended December 31, 2022 have been audited by Macias Gini & O’Connell LLP, an independent registered public accounting firm, as stated in their reports. Such financial statements have been so included in reliance upon the reports of such firms given upon their authority as experts in accounting and auditing.

Table of Contents **PART II** **INFORMATION NOT REQUIRED IN PROSPECTUS** **ITEM 13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION** We will pay all expenses in connection with registration and sale of the common stock by the Selling Securityholders. The estimated expenses of issuance and distribution are set forth below: Item Amount to be paid SEC registration fee \$823 Legal fees and expenses 2,500 Accounting fees and expenses 5,000 Miscellaneous expenses 1,000 Total \$9,323

ITEM 14. INDEMNIFICATION OF DIRECTORS AND OFFICERS Section 1 of Article VI of our Articles of Incorporation provides that, to the fullest extent permitted by the General Corporation Law of the State of Delaware we will indemnify our officers and directors from and against any and all expenses, liabilities, or other matters. Section 2 of Article VI of our Articles of Incorporation provides that, to the fullest extent permitted by law, no director or officer shall be personally liable to the corporation or its shareholders for damages for breach of any duty owed to the corporation or its shareholders. Article XI of our Amended and Restated Bylaws further addresses indemnification of our directors and officers and allows us to indemnify our directors and officers in the event they meet certain criteria in terms of acting in good faith and in an official capacity within the scope of their duties, when such conduct leads them to be involved in a legal action. Insofar as indemnification for liabilities arising under the Securities Act of 1933 (the “Act”) may be permitted to directors, officers and controlling persons of the small business issuer pursuant to the foregoing provisions, or otherwise, the small business issuer has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.

ITEM 15. RECENT SALES OF UNREGISTERED SECURITIES In the last three fiscal years and subsequent interim periods, we issued the following securities: On June 8, 2023, we issued 150,000 shares of our common stock for Restricted Stock Units that vested during 2023. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investors are sophisticated, familiar with our operations, and there was no general solicitation or advertising. On May 10, 2023, noteholders elected to convert a total of \$341,999 (the “Conversion Amount”) pertaining to the 2023 Debt Offering into 150,000 shares of the Company’s common stock at \$2.28 per share. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investors are sophisticated, familiar with our operations, and there was no general solicitation or advertising. On April 1, 2023, we issued 35,000 shares of our common stock for Restricted Stock Units that vested during 2023. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investor is sophisticated, familiar with our operations, and there was no general solicitation or advertising.

Table of Contents On March 9, 2023, the Company entered into a Debt Offering pursuant to a Purchase Agreement (the “Agreement”) and Registration Rights Agreement with institutional investors. The Debt Offering closed on March 9, 2023. The Debt Offering includes 15% Original Issue Discount Convertible Notes (the “Notes”) and Common Stock Purchase Warrants (the “Warrants”). Aegis Capital Corp. acted as sole placement agent for the Debt Offering. Under the terms of the Agreement, the Company received \$3,000,000 from the Purchasers and in exchange issued the Notes in principal amounts of \$3,529,412 and Warrants to purchase up to 386,998 shares of the Company’s common stock. The Notes are convertible voluntarily by the Purchaser at any time the principal amounts are outstanding into shares of our common stock, at a conversion price \$2.28. The Notes are due March 10, 2025, and accrue interest quarterly at 5% per annum. The accrued interest is payable by way of inclusion in the convertible amount. The Warrants are exercisable at any time through March 9, 2028, into shares of the Company’s common stock at an exercise price of \$2.52 per share. The Company received approximately \$2,500,000 of net proceeds from the Debt Offering after offering related costs. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investor is accredited, familiar with our operations, and there was no general solicitation or advertising. On January 1, 2023, the Company entered into a six-month agreement with a consultant to provide investor services and in exchange issued 225,000 shares of restricted common stock and 225,000 warrants to purchase common stock of the Company at an exercise price of \$1.35 per warrant. The warrants expire three years from the date of issuance. On September 30, 2022 pursuant to the Adjustment terms of the March 2022 Armistice Warrant and the September 2021 Armistice Warrant, as a result of entering into the PIPE Offering, we issued an aggregate 1,750,225 warrants (the “Armistice Warrants”) consisting of (i) 1,400,180 warrants pursuant to the Adjustment terms under the September 2021 Armistice Warrant, and (ii) 350,045 warrants pursuant to the Adjustment terms of March 2022 Armistice Warrant. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investor is accredited, familiar with our operations, and there was no general solicitation or advertising. On September 28,

2022, we entered into a PIPE Offering pursuant to a Securities Purchase Agreement with institutional investors for aggregate gross proceeds of approximately \$6 million, before deducting fees to Aegis Capital Corp., the exclusive placement agent in the PIPE Offering, and other expenses payable by the Company. Pursuant to the PIPE Offering, which closed on September 30, 2022, we issued 1,925,677 Non Pre-Funded Units and 2,128,378 Pre-funded Units at a purchase price of \$1.48 per unit priced at-the-market under Nasdaq rules. The Prefunded Units were sold at the same price less the Prefunded Warrant exercise price of \$0.001. Each Non-Prefunded Unit and Prefunded Unit consists of one share of common stock (or common stock equivalent) and one non-tradable Non Prefunded exercisable for one common stock at a price of \$1.35 subject to adjustments pursuant to the Non Prefunded Warrant Agreement. Each Prefunded Unit consists of one share of common stock and one non-tradable Prefunded Warrant exercisable for one common stock at a price of \$1.35 less the Prefunded Warrant exercise price of \$0.001 pursuant to the Prefunded Warrant Agreement. The Non Prefunded Warrants have a term of seven years from the issuance date and the Prefunded Warrants expire until the Prefunded Warrants are exercised in full. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investors are accredited, familiar with our operations, and there was no general solicitation or advertising. On August 3, 2022, in exchange for a settlement of a general mutual release of employment and application claims we issued to a prior employee a warrant for 10,000 shares of our common stock at an exercise price of \$4.25 per share which expires August 3, 2025. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investor is accredited, familiar with our operations, and there was no general solicitation or advertising. On June 7, 2022, we issued 16,666 shares of our common stock for restricted stock units that vested in connection with our uplist to Nasdaq. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investor is accredited, familiar with our operations, and there was no general solicitation or advertising. On June 7, 2022 and June 29, 2022, we issued 300,000 and 500,000 shares of our common stock, respectively, for professional services. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investors were accredited, familiar with our operations, and there was no general solicitation or advertising. On March 30, 2022, in connection with a Waiver Agreement we entered into with Armistice Capital Master Fund Ltd. the holder of an 18% Original Issue Discount Convertible Debenture in the principal amount of \$3,048,780.50, we issued a second common stock purchase warrant, or the March 2022 Armistice Warrant to purchase up to 101,626 additional shares of our common stock expiring March 29, 2029, and extended the Termination Date of the September 2021 Armistice Warrant for 406,504 shares of our common from September 28, 2026 to September 28, 2028. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investor is accredited, familiar with our operations, and there was no general solicitation or advertising. On March 3, 2022 we issued 7,917 shares of our common stock under the terms of a \$47,500 convertible note payable dated March 6, 2020 with interest at 5%, due March 6, 2022 and convertible at \$6 per share. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investor is sophisticated, familiar with our operations, and there was no general solicitation or advertising. On March 1, 2022, we entered into Share Exchange Agreements with David Gandini, one of our officers and directors, and Gary Graham, our largest shareholder, to exchange 333,334 and 666,667 shares of our common stock into 1,000,000 shares and 2,000,000 shares of our Series B Preferred Stock, respectively. These stock exchanges of common stock for preferred stock were done as conditions of our planned underwritten offering and planned listing on Nasdaq. The shares of our Series B Convertible Preferred Stock have liquidation preference over our common stock, receive dividends in pari passu with our common stockholders, are convertible into shares of our common stock on a 3-for-1 basis, and vote on an as converted basis. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investors are sophisticated, familiar with our operations, and there was no general solicitation or advertising. On January 12, 2022 we issued 16,667 shares of our common stock for Restricted Stock Units that vested during 2021. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investor is sophisticated, familiar with our operations, and there was no general solicitation or advertising. On January 10, 2022, in connection with hiring Mr. Wenzel we entered into an Executive Employment Agreement with Mr. Wenzel. Under the terms of his Employment Agreement, Mr. Wenzel will serve as our Chief Financial Officer until January 1, 2024, unless he is terminated pursuant to the termination provisions set forth in his agreement. Under the terms of his Employment Agreement, Mr. Wenzel will perform services for us that are customary and usual for a chief financial officer of a company, in exchange for: (i) an annual base salary of \$175,000, (ii) incentive stock options under our 2019 Equity Incentive Plan to acquire 66,667 shares of our common stock, at an exercise price of \$7.755, which is equal to 110% of the fair market value of our common stock on January 10, 2022 (the date the options were eligible to be issued under Mr. Wenzel's Employment Agreement), with the stock options to vest in 8 equal quarterly installments of 8,334 shares during the two-year term of the Employment Agreement, with a ten year term, and (iii) 16,667 Restricted Stock Units under our 2019 Equity Incentive Plan, which will vest upon the end of any relevant lockup period involving Company securities owned by Mr. Wenzel after we uplist to a national exchange (NASDAQ, NYSE, etc.). The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investor is sophisticated, familiar with our operations, and there was no general solicitation or advertising. On December 7, 2021, in exchange for Sandy Shoemaker agreeing to serve on our Board of Directors, we issued Sandy Shoemaker options to acquire 8,334 shares of our common stock under our 2019 Equity Incentive Plan, at an exercise price of \$10.065 per shares and vest equally over one year. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investor is sophisticated, familiar with our operations, and there was no general solicitation or advertising. On December 7, 2021, in exchange for Sandy Shoemaker agreeing to chair the Audit Committee of our Board of Directors we issued Sandy Shoemaker options to acquire 16,667 shares of our common stock under our 2019 Equity Incentive Plan, at an exercise price of \$10.065 per shares and vest equally over two years. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investor is sophisticated, familiar with our operations, and there was no general solicitation or advertising. On October 18, 2021, we entered into an Executive Employment Agreement with Michael Watson (the Watson Agreement) to serve as our Executive Vice President of Sales and Marketing and Revenue Officer. Under the terms of the Watson Agreement, Mr. Watson performs services for us that are customary and usual for a EVP of sales and marketing of a company, in exchange for: (i) a base salary of \$175,000 and his eligible to participate in any executive bonus plans, with a target bonus of \$75,000, and (ii) incentive stock options under our 2019 Equity Incentive Plan to acquire up to 83,334 shares of our common stock at \$9.21 per share (110% of fair market value on the date of grant), which options vest in equal quarterly installments over a two year period. The Watson Agreement is for a two-year term. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investor is sophisticated, familiar with our operations, and there was no general solicitation or advertising. On August 17, 2021, we entered into an Executive Employment Agreement with Scott Bennett (the Bennett Agreement) to serve as our Executive Vice President of Business Operations beginning on October 18, 2021. Under the terms of the Bennett Agreement, Mr. Bennett performs services for us that are customary and usual for a EVP of business operations of a company, in exchange for: (i) a base salary of \$175,000, (ii) incentive stock options under our 2019 Equity Incentive Plan to acquire up to 33,334 shares of our common stock at \$9.21 per share (110% of fair market value on the date of grant), which options vest in equal quarterly installments over a two year period, and (iii) 16,667 restricted stock units under our 2019 Equity Incentive Stock Plan, which will vest upon the earlier of (a) the expiration of any lock-up period that includes any of our securities owned by the Advisor after the uplist of the Corporation to a national exchange (NASDAQ, NYSE, etc.) or (b) January 1, 2023. The Bennett Agreement is for a two year term. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The

investor is sophisticated, familiar with our operations, and there was no general solicitation or advertising.Â Prior to hiring Mr. Bennett has an executive officer, Mr. Bennett was granted (i) 3,334 restricted stock units pursuant to a prior consulting arrangement with us, and (ii) a stock option to acquire 33,334 shares of our common stock at an exercise price of \$10.131 under a prior employment agreement with us. The restricted stock units were issued under our 2019 Equity Plan and vest upon the earlier of (i) the expiration of any lock-up period that includes any of our securities owned by the Advisor after the uplist of the Corporation to a national exchange (NASDAQ, NYSE, etc.) or (ii) January 1, 2023. The stock options were also issued under our 2019 Equity Incentive Plan and vest in equal installments, monthly over a thirty six (36) month period beginning May 17, 2021. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investor is sophisticated, familiar with our operations, and there was no general solicitation or advertising.Â On September 28, 2021, we closed a financing transaction with Armistice Capital Master Fund Ltd. (the “Purchaser”). Under the terms of the financing, we received \$2,500,000 from the Purchaser and in exchange issued the Purchaser an 18% Original Issue Discount Convertible Debenture in the principal amount of \$3,048,780.50 (the “Debenture”) and a Common Stock Purchase Warrant (the Original Warrant) to purchase up to 406,504 shares of our common stock. The Debenture is convertible: (a) voluntarily by the Purchaser at any time into shares of our common stock at the lesser of (i) 100% of the closing price our common stock on the trading day immediate prior to the Closing Date under the Debenture, or (ii) 75% of the average VWAP of our common stock (representing a 25% discount) during the 5 trading day period immediately prior to the applicable conversion date (on an as adjusted basis giving effect to any splits, dividend and the like during such 5 Trading Day period) (the “Conversion Price”), or (b) automatically upon the occurrence of a Qualified Offering (as defined in the Debenture) into shares of our common stock at the lesser of: (i) the Conversion Price or (ii) 75% of the offering price of the securities offered in the Qualified Offering. The Debenture matures on March 27, 2022, does not accrue interest unless there is an event of default under the terms of the Debenture, and contains industry standard default and other provisions. The Warrant is exercisable at any time in the next five (5) years into shares of our common at an exercise price of \$6.00 per share, unless an event of default occurs, at which time the exercise price will adjust to \$1.00 per share. The Warrant contains a cashless exercise provision but only in the event we fail to have an effective registration statement registering the shares underlying the Warrant at any time beginning six (6) months from the date of the Warrant. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investor is accredited, familiar with our operations, and there was no general solicitation or advertising.Â 19Table of ContentsÂ From March 2021 through May 31, 2021, we conducted a “Unit” offering under Rule 506 of Regulation D, with each Unit consisting of a \$50,000 principal amount convertible debenture (the “Secured Debentures”) and a warrant (the “Warrant”) to purchase 8,334 shares of our common stock. The holders of the Secured Debentures and the Warrants are the Selling Securityholders herein. The Secured Debentures mature two (2) years after issuance. The Secured Debentures will not be redeemable but contain an automatic conversion feature, which will cause all principal and interest due under the Debenture to automatically convert if our common stock closes at or above \$6.00 per share on NASDAQ for five (5) consecutive trading days. Interest on each investor’s Secured Debenture accrues at a rate of 12% per annum, beginning on the date we have access to the investor’s funds. At the date of their investment, investors elected to have the interest due under the Secured Debenture paid in cash monthly or have the interest accrue and be payable on the maturity date of the Secured Debenture. For investors that elect to accrue the interest due under the Secured Debenture, the interest will be paid in cash or may be converted into shares of our common stock under the same terms as the principal amount on the maturity date. The Secured Debentures will be convertible at any time, and from time to time, beginning on the date of issuance, into shares of our common stock. The Secured Debentures will be convertible at nine dollars (\$9.00) per share; provided, however, that the right of conversion will be limited by the terms of the Secured Debentures to the extent necessary to ensure that each Debenture holder will never beneficially own more than 4.9% of our class of common stock at any one time while any portion of the holder’s Debenture remains outstanding. The repayment of the Secured Debentures is secured by our current patent and patent applications. The Warrant attached to each Unit gives the investor the right to purchase 8,334 shares of our common stock. The Warrants are exercisable at any time, and from time to time, beginning on the date of issuance and expiring two (2) years after issuance, into shares of our common stock at an exercise price of nine dollars (\$9.00) per share. In the event our common stock closes at or above \$6.00 per share on NASDAQ for five (5) consecutive trading days then we have the right to notify the holder of the Warrants that we plan to purchase the Warrants for \$0.30 each, which begins a sixty (60) day period for the holder to exercise the Warrants or we may purchase them for \$0.30 each. Under this offering, we issued secured convertible promissory notes totaling \$2,005,000 to 25 non-affiliated investors, and one then-affiliate investor “Mr. Ford Fay, one of our directors (\$50,000) and additional investors that are now affiliates - Mr. James Bardy (through an entity he controls entitled Financial House, LLC) (\$100,000) and Mr. Scott Bennett, our Executive Vice-President of Operations (\$50,000), and warrants to purchase 334,167 shares of our common stock with the notes and warrants having the terms described above. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investor is accredited, familiar with our operations, and there was no general solicitation or advertising.Â In October 2020, we entered into an Advisory Agreement with Steven Beabout, a member of our Board of Directors, under which he agreed to provide us with strategic legal advice in relation to certain business and legal matters for a period of sixteen (16) months. In exchange for his services, we agreed to issue him 25,000 restricted stock units. The restricted stock units were issued under our 2019 Equity Plan and vest upon the earlier of (i) the expiration of any lock-up period that includes any of our securities owned by the Advisor after the uplist of the Corporation to a national exchange (NASDAQ, NYSE, etc.) or (ii) January 1, 2023. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investor is sophisticated, familiar with our operations, and there was no general solicitation or advertising.Â In November 2020 and February 2022, in consideration of Steven Beabout’s work as Chairman of the Compensation Committee of our Board of Directors, we agreed to issue Mr. Beabout 30,000 and 25,000 restricted stock units, respectively. The restricted stock units were issued under our 2019 Equity Plan and vest upon the earlier of (i) the expiration of any lock-up period that includes any of our securities owned by the Advisor after the uplist of the Corporation to a national exchange (NASDAQ, NYSE, etc.) or (ii) January 1, 2023. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investor is sophisticated, familiar with our operations, and there was no general solicitation or advertising.Â In connection with closing the transaction with IDTEC detailed herein, we issued a convertible promissory note totaling approximately \$1,500,000 to IDTEC. The promissory note was convertible any time by the holder into shares of our common stock at a conversion price of \$1.50 per share, subject to anti-dilution protection against any future securities we may issue at an effective price of less than \$0.50 per share. On November 17, 2020, IDTEC converted the total of \$1,551,514 of principal and interest due under the promissory note into 1,034,343 shares of our common stock. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investor is accredited, familiar with our operations, and there was no general solicitation or advertising. At the closing of the same transaction, we also issued Warrant to Purchase Common Stock to IDTEC, under which IDTEC can purchase up to 106,667 shares of our common stock at an exercise price of \$1.50 per share. The issuance of these securities was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The investor is accredited, familiar with our operations, and there was no general solicitation or advertising.Â These issuances were made in reliance on an exemption from registration set forth in Section 4(a)(2) of the Securities Act, as transactions by an issuer not involving a public offering.Â 20Table of ContentsÂ ITEM 16. EXHIBITSÂ The following exhibits are filed as part of this registration statement:Â ExhibitReferenceFiled or FurnishedNumberExhibit DescriptionFormExhibitFiling DateHerewith3.1Articles of Incorporation of Imagine Media, Ltd.SB-23.101/31/20083.2Articles of Amendment to Articles of Incorporation to TransBiotech, Inc.S-13.211/06/20123.3Certificate of Amendment to Certificate of

Incorporation filed with the State of Delaware on May 25, 201710-KÂ 3.3Â 02/06/20193.4Amended and Restated Bylaws of SOBR Safe, Inc.8-KÂ 3.1Â 11/19/20193.5Certificate of Amendment to Certificate of Incorporation of TransBiotech, Inc. changing name to SOBR Safe, Inc., effecting 1-for-33.26 reverse stock split and decreasing authorized common stock to 100M shares8-KÂ 3.1Â 06/11/20204.1Form of Representativeâ€™s Warrant between SOBR Safe, Inc. and Aegis Capital Corp. 8-KÂ 4.1Â 05/19/20224.2Warrant Agency Agreement between SOBR Safe, Inc. and Equiniti Trust Company dated May 17, 20228-KÂ 4.2Â 05/19/20224.3Form of Unit Warrant, issued May 18, 2022 8-KÂ 4.3Â 05/19/20225.1**A Legal Opinion of Lucosky Brookman LLPÂ Â Â Â Â 10.1TransBiotech, Inc. 2019 Equity Incentive Plan8-K10.111/19/201910.2*Employment Agreement with David Gandini dated October 25, 20198-K10.311/19/201910.3Amendment No. 1 to Asset Purchase Agreement dated March 23, 2020 by and between IDTEC, LLC and TransBiotech, Inc.10-QÂ 10.12Â 05/26/202010.4Form of Convertible Promissory Note Issued to IDTEC, LLC at Close of Asset Purchase Transaction8-KÂ 10.3Â 06/11/202010.5Waiver Under Asset Purchase Agreement and Post-Closing Covenant Agreement dated June 5, 2020 by and between IDTEC, LLC and TransBiotech, Inc. 8-KÂ 10.4Â 06/11/202010.6Warrant to Purchase Common Stock dated June 5, 2020 issued to IDTEC, LLC8-KÂ 10.5Â 06/11/202010.7*Advisory Agreement with Steven Beabout dated October 9, 202010-KÂ 10.16Â 03/31/202110.818% Original Issue Discount Convertible Debenture issued by SOBR Safe, Inc. to Armistice Capital Master Fund Ltd. dated September 27, 2021 8-KÂ 10.1Â 10/01/202110.9Warrant to Purchase Common Stock issued by SOBR Safe, Inc. to Armistice Capital Master Fund Ltd. dated September 27, 2021 8-KÂ 10.2Â 10/01/202110.10Securities Purchase Agreement by and between SOBR Safe, Inc. and Armistice Capital Master Fund Ltd. dated September 27, 2021 8-KÂ 10.3Â 10/01/202110.11Registration Rights Agreement by and between SOBR Safe, Inc. and Armistice Capital Master Fund Ltd. dated September 27, 2021 8-KÂ 10.4Â 10/01/202110.12Form of â€œ Secured Convertible Debenture issued by SOBR Safe, Inc. in \$2M Regulation D OfferingS-1/AÂ 10.21Â 12/01/202110.13Form of â€œ Warrant issued by SOBR Safe, Inc. in Regulation D OfferingS-1/AÂ 10.22Â 12/01/202110.14*Executive Employment Agreement with Scott Bennett dated August 17, 2021S-1/AÂ 10.24Â 01/19/2022Â 21Table of ContentsÂ 10.15*Executive Employment Agreement with Michael Watson dated October 11, 2021S-1/AÂ 10.25Â 01/19/202210.16*Executive Employment Agreement with Gerard Wenzel dated January 1, 2022 8-KÂ 10.1Â 01/19/202210.17Form of Share Exchange Agreement with David Gandini and Gary Graham for Series B Preferred Stock S-1/AÂ 10.28Â 03/17/202210.18Common Stock Purchase Warrant issued by SOBR Safe, Inc. to Armistice Capital Master Fund Ltd dated March 30, 2022S-1Â 10.30Â 09/16/202210.19Waiver by and between SOBR Safe, Inc. and Armistice Capital Master Fund Ltd. dated March 30, 2022 8-KÂ 10.1Â 04/01/202210.20Securities Purchase Agreement by and between SOBR Safe, Inc. and Aegis Capital Corp. dated September 28, 20228-KÂ 10.1Â 10/03/202210.21Registration Rights Agreement by and between SOBR Safe, Inc. and Purchasers dated September 30, 2022.8-KÂ 10.2Â 10/03/202210.22Form of Pre-Funded Warrant Agreement by and between SOBR Safe, Inc. and Purchasers dated September 30, 20228-KÂ 10.3Â 10/03/202210.23Form of Warrant Agreement by and between SOBR Safe, Inc. and Purchasers dated September 30, 20228-K/AÂ 10.4Â 10/14/202210.24*Executive Employment Agreement with David Gandini dated January 30th, 2023 8-KÂ 10.1Â 02/03/202310.25Purchase Agreement between SOBR Safe, Inc. and Purchasers dated March 7, 2023 8-KÂ 10.1Â 03/13/202310.26Registration Rights Agreement between SOBR Safe, Inc. and Purchasers dated March 7, 2023 8-KÂ 10.2Â 03/13/202310.27Form of Senior Convertible Note between SOBR Safe, Inc. and Holders dated March 9, 2023 8-KÂ 10.3Â 03/13/202310.28Common Stock Purchase Warrant between SOBR Safe, Inc. and Holders dated March 9, 2023 8-KÂ 10.4Â 03/13/202310.29Amended And Restated Common Stock Purchase Warrant dated September 30, 2022 issued by SOBR Safe, Inc. to Armistice Capital Master Fund Ltd. amending the original warrant dated March 30, 2022S-1Â 10.35Â 10/14/202210.30Amended And Restated Common Stock Purchase Warrant dated September 30, 2022 issued by SOBR Safe, Inc. to Armistice Capital Master Fund Ltd. amending the original warrant dated September 27, 2021S-1Â 10.36Â 10/14/202210.31*Consulting Agreement by and between SOBR Safe, Inc. and Winterstone Group, LLC dated January 21, 20228-KÂ 10.1Â 07/27/202210.32Services Agreement by and between SOBR Safe, Inc. and TraDigital Marketing Group, LLC dated January 18, 20228-KÂ 10.2Â 07/27/202210.33Confirming Agreement by and between SOBR Safe, Inc. and Winterstone Group, LLC dated May 16, 20228-KÂ 10.3Â 07/27/202210.34Confirming Agreement by and between SOBR Safe, Inc. and TraDigital Marketing Group, LLC dated May 16, 20228-KÂ 10.4Â 07/27/202210.35Â Form of Inducement Letter between SOBR Safe, Inc. and the Holder, dated June 4, 2024Â 8-KÂ 10.1Â 06/04/2024Â Â 10.36Â Form of New WarrantÂ 8-KÂ 10.2Â 06/04/2024Â 21.1Â List of SubsidiariesÂ 10-KÂ 21.1Â 04/01/2024Â Â 23.1Â Consent of Independent Registered Public Accounting FirmÂ Â Â Â Â X23.2Â Consent of Independent Registered Public Accounting FirmÂ Â Â Â Â X23.3Â Consent of Lucosky Brookman LLP (Included in Exhibit 5.1)Â Â Â Â Â X24Â Power of Attorney (included in the signature page of this Registration Statement)Â Â Â Â Â X97.1Â Compensation Recovery PolicyÂ 10-KÂ 97.1Â Â 04/01/2024Â Â 101.INSInline XBRL Instance Document.X101.SCHInline XBRL Taxonomy Extension Schema Linkbase Document.X101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.X101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.X101.LABInline XBRL Taxonomy Extension Label Linkbase Document.X101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.X104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).X107Â Filing Fee TableÂ Â Â XÂ *Indicates a management contract or compensatory plan or arrangement.**To be filed by amendmentÂ **XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.Â 22Table of ContentsÂ (b) Financial Statement SchedulesÂ Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or the notes thereto.Â Â UndertakingsÂ Â A.Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by us of expenses incurred or paid by our director, officer or controlling person in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.Â Â Â Â B.The undersigned registrant hereby undertakes:Â Â (1)To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:Â Â (a)To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;Â Â Â (b)To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) (Section 230.424(b) of Regulation S-K) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the â€œCalculation of Registration Feeâ€ table in the effective registration statement; andÂ Â Â (c)To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.Â Â (2)That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of the securities at that time shall be deemed to

[illegible]

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end XML 17 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={ };Show.LastAR=null,Show.showAR=function(a,r,w) {if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)} } if(e).style.display='block';Show.LastAR=e};Show.hideAR=function() {Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style) {}else if(!e.style.display){}else{var d,p,_if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerHTML=p+a.innerHTML.substring(1)}} } XML 18 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a: hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, sans-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, sans-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a: hover { background-color: #fff; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .font { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 20 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 1 16 1 false 0 0 false 3 false false R1.htm 000001 - Document - Cover Sheet http://sobr.com/role/Cover Cover 1 false false All Reports Book All Reports sobr-20240630.xsd sobr-20240630_cal.xml sobr-20240630_def.xml sobr-20240630_lab.xml sobr-20240630_pre.xml sobr_s1.htm sobr_s1img5.jpg sobr_s1img6.jpg sobr_s1img7.jpg sobr_s1img8.jpg http://xbrl.sec.gov/dei/2024 true true JSON 22 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "sobr_s1.htm": { "nsprefix": "sobr", "nsuri": "http://sobr.com/20240630", "dts": { "schema": { "local": ["sobr-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["sobr-20240630_cal.xml"] }, "definitionLink": { "local": ["sobr-20240630_def.xml"] }, "labelLink": { "local": ["sobr-20240630_lab.xml"] }, "presentationLink": { "local": ["sobr-20240630_pre.xml"] }, "inline": { "local": ["sobr_s1.htm"] } } }, "keyStandard": 16, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2024": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 17, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 16 }, "report": { "R1": { "role": "http://sobr.com/role/Cover", "longName": "000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "strong", "p", "td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "sobr_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "strong", "p", "td", "tr", "tbody", "table", "body", "html"], "reportCount": 1, "baseRef": "sobr_s1.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://sobr.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://sobr.com/role/Cover"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://sobr.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1":

{ "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://sobr.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 1", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://sobr.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 2", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://sobr.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://sobr.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://sobr.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://sobr.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r0"] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://sobr.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r0"] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://sobr.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r0"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://sobr.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://sobr.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r0"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://sobr.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r0"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://sobr.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r0"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://sobr.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" } } } ZIP 23 0001477932-24-005243-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-24-005243-xbrl.zip M4\$!#0 (#N;%UEJSMW-AP0 (6 1 "T0]X&FJ9M8C*ID900 M [Z'U-V67\$G.0 _\$^GS? N>N0S/3C?A.B+96*7[M[-! 0903L6!>=>W\$RL6* M,.8@I3?%X!P!>NTS9[0@R#QAG-[B7%FB[0CNDU,J(O M6&DJ73=%_Y/8F:"A- N>+?+["EN"6 \(\@ESR/B26BIC-ECKXX 'I' G P M 'L'08BEWF%)\$99DS30E.I8X1 NJV(HCKNM>1 ?)5FN-? B= (&,&K/G[ZBNU@Q3I5"+R*,C2OJ3_3(B8=NPQ#- M#\$A&554;NDB5:?(&HP@R#!7DWUX[.RUCB:~O)OMO/UH*L-I81S^~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j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~_7K0T9.:7 V2@* A)>7?1YD M0?;M#L@]+OPZM]:2#(NF7I5U#KN@^Z[? M,>^W40E>KT\$H;7.9)"^,D M C): (RVN^I4A+40^D&O <~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

